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26 A Randomized Trial of Hyperfractionation Versus Standard Fractionation In T2 Squamous Cell Carcinoma
of The Vocal Cord
A. Trotti1, T. Pajak2, B. Emami3, E. Hammond4, C. Jones5, W. Morrison6, S. Sagar7, J. Ridge8, K. K. Fu9, K. Ang6
1H. Lee Moffitt Cancer Center, Tampa, FL, 2Radiation Therapy Oncology Group, Philadelphia, PA, 3Loyola University
Medical Center, Maywood, IL, 4IDS Hospital, Salt Lake City, UT, 5Radiation Oncology Center, Sacramento, CA,
6University of Texas MD Anderson Cancer Center, Houston, TX, 7McMaster University, Hamilton, ON, 8Fox Chase Cancer
Center, Philadelphia, PA, 9University of California San Francisco, San Francisco, CA
Purpose/Objective(s): To compare the efficacy of hyperfractionation versus standard fractionation for the treatment of T2N0
carcinoma of the vocal cord.
Materials/Methods: Between April 1996 and July 2003, 250 patients were stratified by substage (T2a vs T2b) and randomly
assigned to receive either hyperfractionation (HFX) to 79.2 Gy in 66 fractions of 1.2 Gy given twice a day, or standard
fractionation (SFX) to 70 Gy in 35 fractions given once a day. The trial was designed to detect a 55% reduction in the yearly
hazard rate for local failure with 80% statistical power. 238 patients were analyzable for outcomes. The median follow-up for
all surviving patients was 4.2 years (range: 0.6 - 9.4). 95% were male, 83% had KPS 90-100, and 63% were T2a.
Results: The five-year local control (LC) rate was modestly higher for HFX (79%) vs SFX (70%), which translates to a 35%
reduction in the hazard rate, but this difference was not statistically significant (p0.11). Five-year disease-free survival (DFS)
was 51 vs 37 % (p0.07). Five-year overall survival was 73 vs 62% (p0.19). HFX had modestly higher rates of acute skin,
mucosal, and laryngeal toxicity. High-grade late effects were uncommon in both groups.
Conclusions: Local control was modestly higher with HFX compared to standard fractionation for T2 carcinoma of the vocal
cord, but the difference did not reach statistical significance. With only 58 local failures, the statistical power of detecting the
observed 35% hazard reduction is only 36%. There was a trend for better disease free survival with HFX. Results are consistent
with other studies showing a modest benefit for altered fractionation in cancers of the H&N.
Author Disclosure: A. Trotti, None; T. Pajak, None; B. Emami, None; E. Hammond, None; C. Jones, None; W. Morrison, None;
S. Sagar, None; J. Ridge, None; K.K. Fu, None; K. Ang, None.
27 Five-year Update on a Randomized Factorial Study on Concurrent and Adjuvant Chemotherapy for
Advanced Nasopharyngeal Carcinoma
D. L. W. Kwong, J. S. T. Sham, G. K. H. Au
Queen Mary Hospital, Pokfulam, Hong Kong
Purpose/Objective(s): To update the results of a randomized factorial trial studying the role of concurrent chemoradiation
(CRT) and adjuvant chemotherapy (AC) for advanced nasopharygngeal carcinoma (NPC).
Five-year rates
SFX HFX p-Value
Endpoint % (95% CI) % (95% CI)
Local Control 70 (62, 79) 79 (71, 87) 0.11
Disease-Free Survival 37 (27, 46) 51 (41, 61) 0.07
Overall Survival 62 (52, 72) 73 (64, 82) 0.19
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Materials/Methods: Ho’s stage T3 or N2 /N3 or  4cm neck node, M0 disease were eligible. Patients were first randomized
to receive CRT or radiotherapy (RT) alone and then further randomized to receive AC or no AC after CRT/RT. CRT involved
UFT (uracil and tegafur in 4:1 molar ratio) 200mg, 3 times a day, during RT. AC consisted of alternating PF (cisplatin
100mg/m2 D1 and 5FU 1g/m2 D1-3) and VBM (vincristine 2mg, bleomycin 30mg and methotrexate 150mg/m2, all on D1) for
6 cycles, after CRT/RT. There were 4 treatment arms: 1. RT, 2. CRT, 3. RT  AC, 4. CRT  AC. To analyze the efficacy
of CRT, arms 1 and 3 were compared with arms 2 and 4 (i.e. RT vs. CRT). To analyze the efficacy of AC, arms 1 and 2 were
compared with arms 3 and 4 (i.e. no AC vs. AC). Analysis was performed according to intention to treat. Persistent disease or
recurrence in nasopharynx (NP) or neck nodes and distant metastases were considered disease failure. Death after recurrence
was considered due to NPC.
Results: From May 1995 to October 2001, 222 patients were recruited. 3 patients were excluded from analysis because
of major protocol violation. Median follow up time of 219 patients in analysis was 65 months. The median age was 45.
Median dose to NP and neck were 68Gy and 66Gy, respectively. There were 55, 53, 54, 57 patients in arm 1, 2, 3, 4
respectively. The 5-year loco-regional control rate and distant metastases-free survival of arm 1, 2, 3, 4 were 64.2%,
74.8%, 78.7%, 81.1% and 74.2%, 85.8%, 67%, 82.4% respectively. The 5-year failure-free and disease-specific survivals
of the 4 arms were and 54%, 69%, 54.6%, 66.4% and 77.1%, 79.8%, 67.7%, 81.4% respectively. CRT significantly
improved the distant metastases-free and failure-free survival (p0.02 and 0.038 respectively). The difference in disease
specific survivals was not statistically significant (p0.075). The use of AC failed to improve survival on all measures.
Multivariate analysis showed only CRT as significant prognostic factor for failure-free survival. Age, T stage, N stage and
CRT were significant prognostic factors for disease-specific survival. The use of AC was not significant for failure-free
or disease-specific survival.
Conclusions: CRT significantly reduced distant metastases and improved failure-free survival for patients with advanced NPC.
There is an improvement of disease-specific survival after adjusting for age and stage of disease. AC failed to improve survival.
The positive effect of CRT was confirmed on long term follow-up.
Author Disclosure: D.L.W. Kwong, None; J.S.T. Sham, None; G.K.H. Au, None.
28 Final Report of SQNP01 - A Phase III Randomized Trial Comparing RT With Chemo-RT for Locally
Advanced Nasopharyngeal Cancer
J. Wee1, E. H. Tan1, B. C. Tai2, H. B. Wong3, S. S. Leong1, T. Tan1, E. T. Chua1, K. M. Lee1, K. W. Fong1, D. Machin1,3
1National Cancer Centre, Singapore, Singapore, 2Yong Loo Lin School of Medicine, National University of Singapore,
Singapore, Singapore, 3Clinical Trials & Epidemiological Research Unit, Singapore, Singapore
Purpose/Objective(s): SQNP01 was designed to confirm the findings of US Intergroup 00-99 - a study showing benefit of
adding chemotherapy to radiotherapy for Nasopharyngeal Cancer (NPC). This is the final report of the study and the 5 year
results of the trial is presented.
Materials/Methods: Between September 1997 and May 2003, 221 patients were randomised to receive radiotherapy alone
(n110) or chemo-radiotherapy (n111). Patients in both arms received 70Gy in 7 weeks using standard radiotherapy portals
and techniques. Those on chemo-radiotherapy received concurrent cisplatin (25mg/m2 Days 1-4) on weeks 1, 4 and 7 of
radiotherapy and adjuvant cisplatin (20mg/m2 Days 1-4) and 5-fluorouracil (1000mg/m2 Days 1-4) every 4 weeks (weeks 11,
15, 19) for 3 cycles following completion of radiotherapy. All patients were analysed by intention-to-treat. Their median
follow-up duration was 4.9 years (interquartile range 3.5 to 6.3 years).
Results: Distant metastasis occurred in 39 patients on radiotherapy alone and 18 on chemo-radiotherapy. Its 5-year cumulative
incidence was 40% for R and 17% for C and this difference of 23% was statistically significant (95% CI 9% to 35%, p0.0014).
Altogether, there were 59 failures in R and 44 in C. These “failures” include those with persistent disease as well as death due
to other causes. The 5-year DFS rates were 45% and 55% for R and C respectively. The median disease-free survival time for
R and C were 4.1 and 7.1 years. The hazard ratio (HR) for DFS was 0.67 (95% CI 0.45 to 0.98, p0.0393). Ninety one (55
R, 36 C) deaths were reported, of which 81 (50 R, 31 C) were disease-related. The 5-year survival rates were 46% and 65%
for R and C respectively. The median overall survival time for R and C were 4.5 and 6.7 years. Patients who were randomized
to receive C thus had a reduced risk of death with a HR of 0.58 (95% CI 0.39 to 0.88, p0.0106).
Conclusions: The 5 year results of this trial continue to show a significant benefit of adding chemotherapy to radiotherapy in
patients with locally advanced NPC. It conclusively confirms the findings of the Intergroup trial, and the result is also applicable
to patients with the endemic form of NPC.
Author Disclosure: J. Wee, None; E.H. Tan, None; B.C. Tai, None; H.B. Wong, None; S.S. Leong, None; T. Tan, None; E.T.
Chua, None; K.M. Lee, None; K.W. Fong, None; D. Machin, None.
Survival analysis comparing CRT vs RT and no AC vs AC
Treatment
No. of
Patients
5-Year Loco-Regional
Control Rate
5-Year Distant
Metastases-Free
Survival
5-Year
Failure-Free
Survival
5-Year Disease
Specific
Survival
RT 109 71.2% 70.7% 54.3% 72.5%
CRT 110 78.2% 84.1% 67.7% 80.5%
Log-rank test
p value 0.22 0.02 0.038 0.075
No AC 108 69.4% 79.8% 61.3% 78.5%
AC 111 80% 75.1% 60.8% 74.6%
Log-rank test
p value 0.078 0.26 0.99 0.78
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